May 17, 2020

Google Australia leads charge in improving STEM studies

healthcare
STEM
Australia
Google
Admin
2 min
The 2014 U.S. Census Bureau report found that 75 percent of STEM graduates do not work in STEM industries.
It appears Google is beginning to invest in Australias children.

As our sister site Business Review Australia recently wrote, the tech giants philanthr...

It appears Google is beginning to invest in Australia’s children.

As our sister site Business Review Australia recently wrote, the tech giant’s philanthropic organisation (Google.org) announced its pledge to donate $1 million toward the science, technology, engineering and math (STEM) educational industry in Australia.

In a move is expected to develop career programs and hands-on training  for girls, indigenous Australians and underprivileged students, the funds will be split between FIRST Robotics, Australian Indigenous Mentoring Experience (AIME) and Engineers Without Borders Australia.

The three non-profit organizations have started programs that intend to improve the lives of 10,000 Aussie children from lower-class backgrounds to pursue careers in STEM.

RELATED TOPIC: Google’s new wearable is a health tracker designed just for doctors

When compared to several other countries with similar economies, Australia ranks well behind in science and innovation in a report by the Office of the Chief Scientist.

For years these educational fields have been looked upon as significant to the nation’s future, and increased training would be a great boost.

“There is a universal agreement that no one knows what the jobs of tomorrow are going to be, but what there is consensus on is that the jobs of tomorrow will disproportionately have some STEM factor associated with them,” said Google Australia managing director Maile Carnegie.

RELATED TOPIC: Google's New Wristband Could Treat Parkinson's and Cancer

Google, which employs over 600 engineers in Australia, says the donation is intended to expand the existing program’s geographic reach while connecting young Aussie engineers to youth, school and community groups throughout regional Australia.

The majority of the funds will go toward assisting the organization to reach 6,500 children, 1,400 parents and 500 teachers in 38 different locations across Australia.

In the United States, the Nesbitt Discovery Academy in Asheville, N.C., has interest among potential students increasing at a rapid pace. This year had about twice as many applicants compared to 2014, as the number of students increased from about 140 to around 270.

RELATED TOPIC: Google, Biogen Idec Unite to Bring New Research to Multiple Sclerosis

The healthcare industry has suffered in recent years from a shortage of talent in math and science fields. In fact, the 2014 U.S. Census Bureau report found that 75 percent of STEM graduates do not work in STEM industries.

It appears more and more countries around the world are putting an emphasis in raising awareness of the STEM industry.

Let's connect!   

Read the latest edition of Healthcare Global magazine!

 

Share article

Jun 22, 2021

Bachem turns 50 - a timeline

pharma
supplychain
peptides
medication
3 min
As Bachem turns 50, we take a look at the company's history

Bachem, a supplier to pharmaceutical and biotechnology companies worldwide, is celebrating its 50th anniversary this month. We take a look at the Swiss company's history.  

1971 - beginnings

Bachem is founded by entrepreneur Peter Grogg in Liestal, a small town near Basel in Switzerland. Grogg started the firm with just two employees, and with a focus on peptide synthesis - peptides are composed of amino acids that have a variety of functions treating health conditions such as cancer and diabetes. 

1977 - 1981 - early growth

Bachem moves its headquarters to the Swiss town of Bubendorf, with eight employees. In 1978 the company produces peptides for use in medicines for the first time. In 1981 production capacity triples and the workforce grows to 150. 

 1987 - 1996 - worldwide expansion

The company expands into the US with Bachem Bioscience, Inc. in Philadelphia. To strengthen its presence in Europe, Bachem opens sales and marketing centres in Germany in 1988. 

Further sales centres open in France in 1993. By 1995 the company employs 190 people. In 1996 it acquires the second largest manufacturer of peptides in the world and forms Bachem California with a site in Torrance. 

 1998 - 2003 - Bachem goes public

Bachem company goes public and lists shares on the Swiss Stock Exchange. Further acquisitions include Peninsula Laboratories, Inc, based in California, and  Sochinaz SA, a Swiss-based manufacturer of active pharmaceutical ingredients.  By 2001, the company has 500 employees and sales reach 141 million CHF.

In 2003 the organisation is given a new legal holding structure to support its continued growth, which remains in place to this day. 

2007 - 2013 - acquisitions

Bachem acquires a brand by Merck Biosciences for ready-to-use clinical trial materials and related services. 

In 2013, together with GlyTech, Inc. Bachem announces the development of a new amino acid that can help to treat multiple sclerosis, with a world market of more than $4 billion. 

In 2015 it acquires the American Peptide Company (APC), which becomes integrated into Bachem Americas. 

2016 - 2019 - a global leader

In 2016 the group opens a new building dedicated to R&D projects and small series production in Bubendorf. With a total of 1,022 employees, the workforce exceeds the 1,000 mark for the first time in the company’s history. Sales are over the 200 million mark for the first time at 236.5 million CHF.
Bachem expands into Asia with the establishment of a new company in Tokyo called Bachem Japan K.K. 

By 2019 Bachem has a growing oligonucleotide portfolio - these are DNA molecules used in genetic testing, research, and forensics. It is hoped this will become a significant product range in the future. 

2020 - COVID-19

Despite the COVID-19 pandemic, Bachem secures its supply of active ingredients, and even increases it in critical areas. Sales exceed the 400 million Swiss franc mark for the first time, and  272 new employees are hired.  

2021 - a milestone anniversary

Bachem celebrates its 50th anniversary and position as a global leader in the manufacture of peptides. While it  remains headquartered in Bubendorf, the company employs 1,500 people at six locations worldwide. In the next five years there are  plans to continue expanding. 

Commemorating the company's anniversary, Kuno Sommer, Chairman of the Board of Directors, said: "Bachem's exceptional success story from a small laboratory to a global market leader is closely linked to Peter Grogg's values, and has been shaped by innovation, consistent quality and cost awareness, as well as by entrepreneurial vision."

Share article